NBIX to start Phase IIb in diabetes

Neurocrine (NBIX) said it will begin this quarter a double-blind, placebo-controlled, international pivotal Phase IIb trial of its NBI-6024 to treat Type I diabetes in up to 400 patients. NBI-6024 is ...